SCM
RARE icon

Sterling Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Sterling Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.8K Buy
1,223
+563
+85% +$14K ﹤0.01% 1636
2026
Q1 		$13.8K Hold
660
– – ﹤0.01% 2202
2025
Q4 		$15.2K Buy
660
+524
+385% +$17.2K ﹤0.01% 2384
2025
Q3 		$4.09K Sell
136
-1
-0.7% -$30 ﹤0.01% 2821
2025
Q2 		$4.98K Sell
137
-154
-53% -$5.55K ﹤0.01% 2517
2025
Q1 		$10.5K Sell
291
-1,166
-80% -$48.5K ﹤0.01% 1845
2024
Q4 		$61.3K Sell
1,457
-183
-11% -$9.08K ﹤0.01% 1559
2024
Q3 		$91.1K Buy
+1,640
New +$83.5K ﹤0.01% 1407

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Sterling Capital Management's RARE Position: Q2 2026 in Review

Sterling Capital Management increased its Ultragenyx Pharmaceutical (RARE) stake by 85% in Q2 2026, buying an estimated $14K and bringing the position to 1,223 shares worth $40.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1636.

Sterling Capital Management first reported a position in RARE in Q3 2024 and has held it in 8 quarters since. The position peaked at $91.1K in Q3 2024. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Sterling Capital Management held 1,223 shares of Ultragenyx Pharmaceutical worth $40.8K as of Q2 2026.
  • Sterling Capital Management bought 563 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $14K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1636 holding.
  • Sterling Capital Management first reported a position in Ultragenyx Pharmaceutical in Q3 2024 and has held it in 8 quarters since.
  • Sterling Capital Management's Ultragenyx Pharmaceutical position peaked at $91.1K in Q3 2024.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.